11.02.16
Charles River Laboratories
3Q Revenues: $425.7 million (+22%)
3Q Earnings: $38.0 million (flat)
YTD Revenues: $1.2 billion (+20%)
YTD Earnings: $111.1 million (-6%)
Comments: Research Models and Services (RMS) revenues were $120.9 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenues were $215.8 million, up 36% driven primarily by the acquisitions of WIL Research and Oncotest, which contributed 35% to DSA revenue growth. Revenue for the Manufacturing segment was $89.0 million, up 21% driven primarily by the Microbial Solutions and Biologics Testing Solutions businesses. The acquisitions of Blue Stream Laboratories, Celsis, and WIL Research’s contract development and manufacturing services contributed 10.5% to growth in the quarter.
3Q Revenues: $425.7 million (+22%)
3Q Earnings: $38.0 million (flat)
YTD Revenues: $1.2 billion (+20%)
YTD Earnings: $111.1 million (-6%)
Comments: Research Models and Services (RMS) revenues were $120.9 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenues were $215.8 million, up 36% driven primarily by the acquisitions of WIL Research and Oncotest, which contributed 35% to DSA revenue growth. Revenue for the Manufacturing segment was $89.0 million, up 21% driven primarily by the Microbial Solutions and Biologics Testing Solutions businesses. The acquisitions of Blue Stream Laboratories, Celsis, and WIL Research’s contract development and manufacturing services contributed 10.5% to growth in the quarter.
